Bevacizumab in ovarian cancer: A critical review of phase III studies

Bevacizumab (BV) is a humanized monoclonal antibody targeting vascular endothelial growth factor and it is the first molecular-targeted agent to be used for the treatment of ovarian cancer (OC). Randomized Phase III trials evaluated the combination of BV plus standard chemotherapy for first-line tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Luigi, Verrico, Monica, Zaccarelli, Eleonora, Papa, Anselmo, Colonna, Maria, Strudel, Martina, Vici, Patrizia, Bianco, Vincenzo, Tomao, Federica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355353/
https://www.ncbi.nlm.nih.gov/pubmed/27852039
http://dx.doi.org/10.18632/oncotarget.13310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355353/
https://www.ncbi.nlm.nih.gov/pubmed/27852039
http://dx.doi.org/10.18632/oncotarget.13310

Ejemplares similares